Skip to main content

Dr. Koithara Varkey Thomas, M.D.

Nephrology (Kidney) (Nephrology Physician)

  • Medicare participating

At a glance

Years since graduation
37
In the NPI registry since
2006
Medicare patients seen, 2024
586

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Nephrology Physician primary
    NC license 200300295

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Nephrology (Kidney) per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
586
Services billed
4,919
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units84017
Insertion of needle into vein for collection of blood sample640377
Established patient office or other outpatient visit, 30-39 minutes508356
Complete blood cell count (red cells, white blood cell, platelets), automated test470314
Kidney function blood test panel348236
Creatinine level to test for kidney function or muscle injury329228
Parathormone (parathyroid hormone) level328232
Automated urinalysis test303239
Magnesium level235168
Vitamin d-3 level212181

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 28 payments worth $542 in total to this clinician.

By company
Travere Therapeutics, Inc.$77.69
Amgen Inc.$75.42
Calliditas Therapeutics US Inc.$75.00
Ardelyx, Inc.$71.22
Akebia Therapeutics Inc$71.16
Otsuka America Pharmaceutical, Inc.$66.05
Novartis Pharmaceuticals Corporation$40.45
Bayer HealthCare Pharmaceuticals Inc.$24.99
By type
Food and Beverage$535
Education$7.47

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 19, 2025Travere Therapeutics, Inc.
Nov 19, 2025
Education
Filspari · Kidney Disease · in-kind
$4.15
Oct 15, 2025Travere Therapeutics, Inc.
Oct 15, 2025
Education
Filspari · Kidney Disease · in-kind
$1.66
Oct 23, 2025Travere Therapeutics, Inc.
Oct 23, 2025
Education
Filspari · Kidney Disease · in-kind
$1.66

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $457,024 in research payments for these studies, mostly to the institutions running them.

  • A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
    AstraZeneca Pharmaceuticals LP
  • A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
    AstraZeneca Pharmaceuticals LP
  • A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
    Vertex Pharmaceuticals Incorporated
  • Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APP…
    AstraZeneca UK Limited
  • A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
    AstraZeneca Pharmaceuticals LP
  • A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
    Vertex Pharmaceuticals Incorporated
  • Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
    Eli Lilly and Company · Withdrawn · NCT06598631
  • A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Jacksonville

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 1, 2020), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1265474209. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.